

-continued

35	40
----	----

```

<210> SEQ ID NO 20
<211> LENGTH: 41
<212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus type 1

<400> SEQUENCE: 20

Ser Thr Cys Ala Arg Pro Tyr Gln Asn Thr Arg Gln Arg Thr Pro Ile
 1             5             10            15

Gly Leu Gly Gln Ser Leu Tyr Thr Thr Arg Gly Arg Thr Lys Ile Ile
          20            25            30

Gly Gln Ala His Cys Asn Ile Ser Gly
      35             40

<210> SEQ ID NO 21
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus type 1

<400> SEQUENCE: 21

Gly Pro Gly Arg Ala Phe
 1             5

<210> SEQ ID NO 22
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus type 1

<400> SEQUENCE: 22

Arg Ile Gln Arg Gly Pro Gly Arg Ala Phe Val Thr Ile Gly Lys
 1             5             10            15

<210> SEQ ID NO 23
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus type 1

<400> SEQUENCE: 23

Asn Asn Asn Thr Arg Lys Ser Ile Arg Ile Gln Arg
 1             5             10

```

What is claimed is:

1. A recombinant, chimeric, particle-forming protein comprising a first amino acid sequence consisting of a self-assembling, particle-forming, yeast retrotransposon Ty p1 amino acid sequence and a second antigenic, amino acid sequence which is incorporated within an immunogenic, surface-exposed region of said yeast retrotransposon Ty p1 amino acid sequence, wherein said surface-exposed regions are selected from the group consisting of amino acids 21-42, 55-74, and 93-142 of the Ty p1 sequence.

2. A particle-forming protein as claimed in claim 1 wherein said second amino acid sequence is incorporated into more than one surface-exposed region.

3. A particle-forming protein as claimed in claim 1 wherein the surface-exposed region is present in the N-terminal half of the first amino acid sequence.

4. The particle-forming protein of claim 1, wherein the surface-exposed epitope is located between amino acids 21-42.

5. The particle-forming protein of claim 1, wherein the surface-exposed epitope is located between amino acids 55-74.

6. The particle-forming protein of claim 1, wherein the surface-exposed epitope is located between amino acids 93-142.

7. The particle-forming protein of claim 4 wherein the second amino acid sequence is inserted between amino acids 30-31.

8. The particle-forming protein of claim 5 wherein the second amino acid sequence is inserted between amino acids 67-68.

9. The particle-forming protein of claim 7 wherein the second amino acid sequence is inserted between amino acids 113-114.

10. The particle-forming protein of claim 7 wherein the second amino acid sequence is inserted between amino acids 132-133.

11. The particle-forming protein of claim 1 wherein the second antigenic, amino acid sequence is obtained from a tumor antigen or aetiological agent.

12. The particle-forming protein of claim 11 wherein the second antigenic, amino acid sequence is obtained from an aetiological agent antigen selected from the group consisting of viral, bacterial, fungal, and parasitic antigens.